Business
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol approximately 756 patients at more than 150 clinical sitesTrial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immun
About this update from Immutep Ltd
[{"type":"image","alt":"Immutep Limited","displaySize":"","headline":null,"caption":"Immutep Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":246,"height":103,"url":"https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIIfOSI4irhaeByOTtn6bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/60325dae98d9e851c4236017024da578","width":246,"height":103}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Trial results will inform potential marketing approval application in non-small cell lung cancer, one of the largest indications in oncology ","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":356,"olType":false},{"type":"text","content":" SYDNEY, AUSTRALIA, March 25, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the first patient has been successfully dosed in the Company’s pivotal TACTI-004 Phase III trial. TACTI-004 will evaluate Immutep’s eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC).","length":644,"tagName":"p"},{"type":"text","content":"Dr. Ina Nordman, who treated the first patient at Calvary Mater Newcastle Hospital in Australia, stated, “We are very excited to participate in this important Phase III trial. Despite advancements in the treatment landscape for non-small cell lung cancer, there remains a high unmet need for new approaches that can safely extend patients’ lives. The anti-cancer immune response driven by efti’s unique mechanism of action as an MHC Class II agonist in combination with KEYTRUDA has led to strong ef...